Please assess the completion status of the following clinical trial:

Trial Title: Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected infection (no clear-cut source of infection) as defined by the treating physician~* Empiric antibiotic treatment~* No clear-cut source of infection by clinical or microbiological criteria~* ICU patient~* Informed consent~Exclusion Criteria:~* Age \<18 years~* Pregnancy~* Hemodynamic instability defined as persistent hypotension, need for on-going aggressive resuscitation and/or vasopressor support to maintain an adequate mean arterial blood pressure~* Need for antibiotic prophylaxis~* Patient withdrawn from empiric antibiotic treatment before Day 4~* Severely immuno-compromised patient (liver cirrhosis (Child-Pugh class C), immunosuppressive drugs after transplantation, neutropenia (absolute neutrophil count \<1000 counts/L), CD-4 count less than 200)~* Patient with suspected bacterial or fungal endocarditis~* Patient with suspected meningitis~* Cardiopulmonary bypass within the last 7 days1)~* Major surgery within the last 7 days (surgery that induces a major inflammatory response such as heart or aortic surgery or major abdominal surgery (i.e. duodenopancreatectomy) or any surgery requiring massive blood transfusion.)~* Multiple trauma within the last 7 days~* Cardiopulmonary resuscitation (CPR) within the last 7 days~* Burns \>20% body surface area~* Patient in terminal status referred for palliative care~* Patient with advanced directives or Do Not Resuscitate (DNR) orders~* Patient who is already enrolled in another therapeutic clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Standard treatment
- PCT (Type: EXPERIMENTAL): PCT guided arm

Based on this trial design, predict the completion outcome and termination type (if applicable).